Michallet, Mauricette, Dreger, Peter, Sobh, Mohamad, Koster, Linda, Hoek, Jennifer, Boumendil, Ariane ORCID: 0000-0002-2552-0542, Scheid, Christof, Fox, Christopher P., Wulf, Gerald, Krueger, William, van Gelder, Michel, Corradini, Paolo, Russo, Domenico, Passweg, Jakob, Schoemans, Helene, Bethge, Wolfgang, Schaap, Nicolaas, Cornelissen, Jan, Browne, Paul ORCID: 0000-0001-5310-1487, Durakovic, Nadira, Muller, Lutz, Montoto, Silvia, Kroger, Nicolaus and Schetelig, Johannes (2020). Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. Bone Marrow Transplant., 55 (5). S. 884 - 891. LONDON: SPRINGERNATURE. ISSN 1476-5365

Full text not available from this repository.

Abstract

The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the median number of treatment lines prior to transplantation was 3 (1-10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1-140). Overall, 40 (71%) patients responded to Ibrutinib; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two-year OS and PFS probabilities were 72% (95% CI: 52-84) and 50% (95% CI: 32-66), respectively. Patients with late relapse after allo-HSCT (>= 24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Michallet, MauricetteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dreger, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sobh, MohamadUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Koster, LindaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hoek, JenniferUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boumendil, ArianeUNSPECIFIEDorcid.org/0000-0002-2552-0542UNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fox, Christopher P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wulf, GeraldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krueger, WilliamUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van Gelder, MichelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Corradini, PaoloUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Russo, DomenicoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Passweg, JakobUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schoemans, HeleneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bethge, WolfgangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schaap, NicolaasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cornelissen, JanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Browne, PaulUNSPECIFIEDorcid.org/0000-0001-5310-1487UNSPECIFIED
Durakovic, NadiraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Muller, LutzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Montoto, SilviaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kroger, NicolausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schetelig, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-334647
DOI: 10.1038/s41409-019-0742-7
Journal or Publication Title: Bone Marrow Transplant.
Volume: 55
Number: 5
Page Range: S. 884 - 891
Date: 2020
Publisher: SPRINGERNATURE
Place of Publication: LONDON
ISSN: 1476-5365
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
STEM-CELL TRANSPLANTATION; HIGH-RISK CLL; TARGETING BTK; T-CELLS; OUTCOMES; FAILURE; DISEASEMultiple languages
Biophysics; Oncology; Hematology; Immunology; TransplantationMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/33464

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item